I guess the unsaid thing about being on track for the trial startup is that POH must be well satisfied that OxyM is technically ready to successfuly meet desired endpoints, otherwise why start the trial if internal lab testing hasn't checked all the right boxes in the first instance.
I'm quietly confident the multi dosing trial will go well.
phase 1 oxymorphone trial begins ann, page-32
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $95.58K | 47.79M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 58466742 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 15489231 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVE (ASX) Chart |